Enterprise Value
82.22M
Cash
31.51M
Avg Qtr Burn
-18.75M
Short % of Float
5.48%
Insider Ownership
9.73%
Institutional Own.
29.87%
Qtr Updated
12/31/22
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Klisyri (Tirbanibulin ointment) Details Skin disease/disorder, Actinic keratosis | Approved Quarterly sales | |
Oral paclitaxel + encequidar Details Metastatic breast cancer, Cancer, Solid tumor/s | NDA FDA meeting | |
Oral Paclitaxel +encequidar Details Angiosarcoma | Phase 2 Data readout | |
Oral Paclitaxel + encequidar w/ dostarlimab Details Cancer, Breast cancer | Phase 2 Update | |
Oral Paclitaxel + KEYTRUDA (Pembrolizumab) Details Non-small cell lung carcinoma, Cancer, Solid tumor/s | Phase 1/2 Update | |
Oral paclitaxel + encequidar w/ ramucirumab Details Gastric cancer | Phase 1b Data readout | |
KUR-501 Details Neuroblastoma | Phase 1 Data readout | |
KUR-502 Details B-cell malignancies | Phase 1 Update | |
Oral topotecan + encequidar Details Solid tumor/s, Cancer | Failed Discontinued | |
Oral irinotecan + encequidar Details Solid tumor/s, Cancer | Failed Discontinued | |
Oral docetaxel + encequidar Details Solid tumor/s, Cancer, Prostate cancer | Failed Discontinued |